FDA Approves Targeted Therapy Combination for Melanoma

0

Just over a month after approving a first-of-its-kind combination therapy for advanced melanoma, the U.S. Food and Drug Administration (FDA) has signed off on another drug combination to treat the disease.

Skin cancer screeningsThe FDA has approved a targeted therapy combination, Cotellic (cobimetinib) and vemurafenib, to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery. The therapy targets a certain type of abnormal gene: BRAF V600E or V600K mutation.

“Treatment for melanoma is advancing at a record pace, with numerous new and exciting options for patients,” says Elizabeth Buchbinder, MD, a physician with Dana-Farber’s Melanoma Treatment Center. “The landscape for metastatic melanoma has been changing dramatically in a setting where there were previously only a few treatments available.”

In early October 2015, the FDA approved the first cancer treatment to combine two immunotherapy drugs: ipilimumab (Yervoy) and nivolumab (Opdivo). The immunotherapeutic combination has been approved to treat certain patients with unresectable or metastatic melanoma. Specifically, it is approved for patients who have tumors that do not harbor the BRAF V600 mutations found in about 50 percent of melanomas.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Judy Wilkins tried four different #chemotherapy regiments over 18 grueling months to try to put her #lymphoma into… https://t.co/hkG0KBDuTD
Dana-Farber @danafarber
RT @KraftBloodDonor: The holidays are often a special time of need for blood and platelet donations. Schedule your life-saving donation now…
Dana-Farber @danafarber
Why is pancreatic cancer so difficult to treat? https://t.co/3DIHEM7iBh #pancreaticcancer https://t.co/SYNrSYfI5B

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.